Stock OASA PHARADR
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

OASA PHARADR Stock Nasdaq

Equities

US67421W1099

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 3.04M 284K Sales 2023 6.61M 617K Capitalization 219M 20.47M
Net income 2022 -357M -33.32M Net income 2023 -129M -12.04M EV / Sales 2022 32.6 x
Net cash position 2022 134M 12.54M Net cash position 2023 77.04M 7.19M EV / Sales 2023 21.5 x
P/E ratio 2022
-0.6 x
P/E ratio 2023
-1.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 61.42%
More Fundamentals * Assessed data

Chart OASA PHARADR

Dynamic Chart

Latest news about OASA PHARADR

Transcript : Vivesto AB - Special Call
Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial CI
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vivesto's International Patent Application for XR-18 Receives Positive Decision CI
Vivesto Gains on Receipt of US Approval for Pilot Clinical Trial of Drug Candidate Paccal Vet MT
Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment CI
Vivesto AB Reports Positive Preclinical Data Supporting Continued Development of Cantrixil CI
Vivesto AB Announces Composition of Nomination Committee CI
Vivesto Abandons Apealea Partnership with Elevar Therapeutics MT
Vivesto AB and Elevar Therapeutics Inc. Sign Agreement Ending Apealea®? Partnership CI
Vivesto AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pharmaceutical Group Vivesto to Delist from Frankfurt Bourse MT
Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Vivesto Halts Patient Enrollment in Phase 1b Study for Prostate Cancer Treatment MT
Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar Study CI
More news

Latest transcript on OASA PHARADR

Logo OASA PHARADR
Vivesto AB - Special Call
More transcripts

Press releases OASA PHARADR

Notice of Annual General Meeting in Vivesto AB AQ
Vivesto to hold live-streamed Paccal Vet R&D Update on March 26 AQ
Vivesto doses first patient in its clinical Paccal Vet trial AQ
Vivesto's international patent application for XR-18 receives positive decision AQ
Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment AQ
More press releases

News in other languages on OASA PHARADR

Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves
More news

Managers and Directors - OASA PHARADR

Managers TitleAgeSince
Erik Kinnman CEO
 Chief Executive Officer 66 23-01-22
Robert Maiorana DFI
 Director of Finance/CFO 64 20-11-30
Heidi Ramstad CTO
 Chief Tech/Sci/R&D Officer 55 21-02-28
Members of the board TitleAgeSince
Isak Peter Zonabend CHM
 Chairman 44 19-03-18
Hege Hellstrom BRD
 Director/Board Member 59 19-09-25
Pål Ryfors BRD
 Director/Board Member 41 22-05-24
More insiders

Company Profile

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Sector
Pharmaceuticals
Calendar
2024-05-22 - Annual General Meeting
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 693B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 584B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 372B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 294B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 211B
NOVARTIS AG Stock Novartis AG
+10.02% 210B
AMGEN INC. Stock Amgen Inc.
+8.49% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VIVE Stock
  4. Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW